ZB021 and ZB022
ZB021
ZB021, a development candidate currently in Investigational New Drug (IND)-enabling studies, is a potentially best-in-class, novel oral IL-17AA/AF inhibitor that blocks IL-17AA homodimer and IL-17AF heterodimer signaling with potential in multiple therapeutic areas, including rheumatology and dermatology. ZB021’s best-in-class potential is supported by robust preclinical data, including high potency observed in vitro and robust efficacy observed in vivo. IL-17AA/AF is a well-established target across a range of autoimmune diseases. An IND submission is planned for ZB021 and a Phase 1 trial is expected to initiate in 2026.
ZB022
ZB022, a development candidate currently in IND-enabling studies, is a potentially best-in-class, oral, brain-penetrant, TYK2-JH2 inhibitor with potential in neuroinflammatory and neurodegenerative diseases. ZB022 is allosteric inhibitor of TYK2, with potentially improved selectivity and specificity and favorable PK/PD observed in preclinical studies. TYK2 inhibition is a well-established mechanism across a range of autoimmune diseases. An IND submission is planned for ZB022 and Phase 1 trial is expected to initiate in 2026.
Our Pipeline
We are advancing two potential autoimmune disease franchise molecules, obexelimab and orelabrutinib, along with other pipeline and partnered programs for patients with autoimmune diseases. View our pipeline.
